The largest premarket stock movers include Carvana, First Solar, and Generac.

Take a look at some of the biggest movers in the premarket:

RBC Capital Markets downgraded Carvana from "outperform" to "sector perform" and cut its stock price target from $155 to $138 per share. The decision was based on valuation and potential challenges in integrating its recent acquisition of Adesa. As a result, Carvana's stock price slid 3.4% in the premarket.

The solar company's stock price dropped 4.8% in premarket trading after Bank of America Securities changed its rating from "neutral" to "underperform." BofA stated that investors may have overestimated the growth prospects and that a new Commerce Department anti-dumping investigation into Asian module manufacturers is unlikely to boost pricing power.

Goldman Sachs has included Generac, the manufacturer of backup generators and other energy-related equipment, on its "Americas Buy List." Goldman highlights Generac's diverse product portfolio, expanding distribution network, and the potential for many of its products to be in the early stages of adoption. Generac's stock price increased by 2.1% in premarket trading.

The cruise line operator reported that the week from March 28 to April 3 was the busiest for new cruise bookings in the company's history, causing Carnival to increase by 3.6% in the premarket.

Twitter's stock price increased by 1.5% in premarket trading after rising 27.1% on Monday. This was due to Elon Musk's announcement that he had acquired a 9.2% stake in the social media company.

The Financial Times reported that Nio is in talks with peers about licensing its battery swapping technology, resulting in a 1.1% increase in the premarket.

Neiman Marcus will receive a $200 million minority stake investment from a luxury fashion e-commerce company as part of a global partnership.

The lighting products and building management systems manufacturer reported quarterly earnings of $2.57 per share, 20 cents above expectations. Additionally, revenue exceeded Wall Street predictions. The company stated that it successfully offset rising materials and freight expenses through price hikes and productivity enhancements.

Barclays upgraded Teva from "equal weight" to "overweight," citing factors such as increased estimates for Teva's biosimilar version of Humira. Teva's stock price increased by 1.5% in premarket trading.